{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:20:08Z","timestamp":1792675208775,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s11926-020-00904-9","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T07:03:08Z","timestamp":1590476588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Reactive Arthritis: Treatment Challenges and Future Perspectives"],"prefix":"10.1007","volume":"22","author":[{"given":"Daniel","family":"Wendling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Chouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"904_CR1","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10067-018-4022-5","volume":"37","author":"A Garc\u00eda-Kutzbach","year":"2018","unstructured":"Garc\u00eda-Kutzbach A, Chac\u00f3n-S\u00fachite J, Garc\u00eda-Ferrer H, Iraheta I. Reactive arthritis: update 2018. Clin Rheumatol. 2018;37:869\u201374. https:\/\/doi.org\/10.1007\/s10067-018-4022-5.","journal-title":"Clin Rheumatol"},{"key":"904_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.idc.2017.01.002","volume":"31","author":"SK Schmitt","year":"2017","unstructured":"Schmitt SK. Reactive arthritis. Infect Dis Clin N Am. 2017;31:265\u201377. https:\/\/doi.org\/10.1016\/j.idc.2017.01.002.","journal-title":"Infect Dis Clin N Am"},{"key":"904_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.autrev.2014.01.005","volume":"13","author":"C Selmi","year":"2014","unstructured":"Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014;13:546\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.005.","journal-title":"Autoimmun Rev"},{"key":"904_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jbspin.2015.06.006","volume":"82","author":"D Wendling","year":"2015","unstructured":"Wendling D, Claudepierre P, Prati C, Dougados M. Spondyloarthritis: a concept or a disease? Joint Bone Spine. 2015;82:387\u20139. https:\/\/doi.org\/10.1016\/j.jbspin.2015.06.006.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"904_CR5","doi-asserted-by":"publisher","first-page":"BSR20191927","DOI":"10.1042\/BSR20191927","volume":"40","author":"H Zeng","year":"2020","unstructured":"Zeng H, Luo B, Zhang Y, Xie Z, Ye Z. Treatment of reactive arthritis with biological agents: a review. Biosci Rep. 2020;40(2):BSR20191927. https:\/\/doi.org\/10.1042\/BSR20191927.","journal-title":"Biosci Rep"},{"key":"904_CR6","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s10067-019-04522-4","volume":"38","author":"KM Hayes","year":"2019","unstructured":"Hayes KM, Hayes RJP, Turk MA, Pope JE. Evolving patterns of reactive arthritis. Clin Rheumatol. 2019;38:2083\u20138. https:\/\/doi.org\/10.1007\/s10067-019-04522-4.","journal-title":"Clin Rheumatol"},{"key":"904_CR7","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1177\/0956462415598251","volume":"27","author":"E Mason","year":"2016","unstructured":"Mason E, Wray L, Foster R, Jamil MS, Guy R, McNulty A, et al. Reactive arthritis at the Sydney Sexual Health Centre 1992-2012: declining despite increasing chlamydia diagnoses. Int J STD AIDS. 2016;27:882\u20139. https:\/\/doi.org\/10.1177\/0956462415598251.","journal-title":"Int J STD AIDS"},{"key":"904_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jbspin.2017.01.013","volume":"85","author":"A Courcoul","year":"2018","unstructured":"\u2022 Courcoul A, Brinster A, Decullier E, Larbre JP, Piperno M, Pradat E, et al. A bicentre retrospective study of features and outcomes of patients with reactive arthritis. Joint Bone Spine. 2018;85:201\u20135. https:\/\/doi.org\/10.1016\/j.jbspin.2017.01.013A bicentric study evaluating retrospectively the changes in patients profile and outcome.","journal-title":"Joint Bone Spine"},{"key":"904_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.reuma.2016.08.001","volume":"14","author":"A Brinster","year":"2018","unstructured":"\u2022 Brinster A, Guillot X, Prati C, Wendling D. Evolution over thirty years of the profile of inpatients with reactive arthritis in a tertiary rheumatology unit. Reumatol Clin. 2018;14:36\u20139. https:\/\/doi.org\/10.1016\/j.reuma.2016.08.001A monocentric study over 30 years, illustrating the stable frequency of patients hospitalized for reactive arthritis.","journal-title":"Reumatol Clin"},{"key":"904_CR10","first-page":"1065","volume":"37","author":"B Lucchino","year":"2019","unstructured":"Lucchino B, Spinelli FR, Perricone C, Valesini G, Di Franco M. Reactive arthritis: current treatment challenges and future perspectives. Clin Exp Rheumatol. 2019;37:1065\u201376 Epub 2019 May 22.","journal-title":"Clin Exp Rheumatol"},{"key":"904_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/1744666X.2017.1233816","volume":"13","author":"JD Carter","year":"2017","unstructured":"Carter JD, Hudson AP. Recent advances and future directions in understanding and treating chlamydia-induced reactive arthritis. Expert Rev Clin Immunol. 2017;13:197\u2013206. https:\/\/doi.org\/10.1080\/1744666X.2017.1233816.","journal-title":"Expert Rev Clin Immunol"},{"key":"904_CR12","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.12659\/msm.904681","volume":"23","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Tang H, Tan C, Zhao H, Liu Y. HLA-B27 correlates with the intracellular elimination, replication, and trafficking of salmonella enteritidis collected from reactive arthritis patients. Med Sci Monit. 2017;23:5420\u20139. https:\/\/doi.org\/10.12659\/msm.904681.","journal-title":"Med Sci Monit"},{"key":"904_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jbspin.2016.02.017","volume":"83","author":"D Wendling","year":"2016","unstructured":"Wendling D. The gut in spondyloarthritis. Joint Bone Spine. 2016;83:401\u20135. https:\/\/doi.org\/10.1016\/j.jbspin.2016.02.017.","journal-title":"Joint Bone Spine"},{"key":"904_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.40359","volume":"70","author":"J Manasson","year":"2018","unstructured":"Manasson J, Shen N, Garcia Ferrer HR, Ubeda C, Iraheta I, Heguy A, et al. Gut microbiota perturbations in reactive arthritis and postinfectious spondyloarthritis. Arthritis Rheumatol. 2018;70:242\u201354. https:\/\/doi.org\/10.1002\/art.40359.","journal-title":"Arthritis Rheumatol."},{"key":"904_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbspin.2017.05.001","volume":"85","author":"D Wendling","year":"2018","unstructured":"Wendling D, Prati C. Spondyloarthritis: an expanding cast of cellular actors. Joint Bone Spine. 2018;85:1\u20133. https:\/\/doi.org\/10.1016\/j.jbspin.2017.05.001.","journal-title":"Joint Bone Spine."},{"key":"904_CR16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/intimm\/dxp052","volume":"21","author":"MS Bharhani","year":"2009","unstructured":"Bharhani MS, Chiu B, Na KS, Inman RD. Activation of invariant NKT cells confers protection against chlamydia trachomatis-induced arthritis. Int Immunol. 2009;21:859\u201370. https:\/\/doi.org\/10.1093\/intimm\/dxp052.","journal-title":"Int Immunol"},{"key":"904_CR17","doi-asserted-by":"publisher","unstructured":"Silva JE, Mayordomo AC, Dave MN, Aguilera Merlo C, Eli\u00e7abe RJ, Di Genaro MS. Dendritic cells of mesenteric and regional lymph nodes contribute to Yersinia enterocolitica O:3-induced reactive arthritis in TNFRp55\u2212\/\u2212 mice. J Immunol. 2020:ji1901137. https:\/\/doi.org\/10.4049\/jimmunol.1901137.","DOI":"10.4049\/jimmunol.1901137"},{"key":"904_CR18","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.38638","volume":"66","author":"H Benham","year":"2014","unstructured":"Benham H, Rehaume LM, Hasnain SZ, Velasco J, Baillet AC, Ruutu M, et al. Interleukin-23 mediates the intestinal response to microbial \u03b2-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol. 2014;66:1755\u201367. https:\/\/doi.org\/10.1002\/art.38638.","journal-title":"Arthritis Rheumatol."},{"key":"904_CR19","doi-asserted-by":"publisher","first-page":"e0193573","DOI":"10.1371\/journal.pone.0193573","volume":"13","author":"AC Mayordomo","year":"2018","unstructured":"Mayordomo AC, Silva JE, Gorlino CV, Arias JL, Ber\u00f3n W, Di Genaro MS. IL-12\/23p40 overproduction by dendritic cells leads to an increased Th1 and Th17 polarization in a model of Yersinia enterocolitica-induced reactive arthritis in TNFRp55\u2212\/\u2212 mice. PLoS One. 2018;13:e0193573. https:\/\/doi.org\/10.1371\/journal.pone.0193573 eCollection 2018.","journal-title":"PLoS One"},{"key":"904_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.clim.2017.03.016","volume":"183","author":"AC Chowdhury","year":"2017","unstructured":"Chowdhury AC, Chaurasia S, Mishra SK, Aggarwal A, Misra R. IL-17 and IFN-\u03b3 producing NK and \u03b3\u03b4-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis. Clin Immunol. 2017;183:207\u201312. https:\/\/doi.org\/10.1016\/j.clim.2017.03.016.","journal-title":"Clin Immunol"},{"issue":"25","key":"904_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1177\/0956462414540617","volume":"2014","author":"EM Carlin","year":"2014","unstructured":"Carlin EM, Ziza JM, Keat A, Janier M. European guideline on the management of sexually acquired reactive arthritis. Int J STD AIDS. 2014;2014(25):901\u201312. https:\/\/doi.org\/10.1177\/0956462414540617.","journal-title":"Int J STD AIDS"},{"key":"904_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3899\/jrheum.121192","volume":"40","author":"CE Barber","year":"2013","unstructured":"Barber CE, Kim J, Inman RD, Esdaile JM, James MT. Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis. J Rheumatol. 2013;40:916\u201328. https:\/\/doi.org\/10.3899\/jrheum.121192.","journal-title":"J Rheumatol"},{"key":"904_CR23","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s00296-013-2794-0","volume":"33","author":"A Kuuliala","year":"2013","unstructured":"Kuuliala A, Julkunen H, Paimela L, Peltomaa R, Kautiainen H, Repo H, et al. Double-blind, randomized, placebo-controlled study of three-month treatment with the combination of ofloxacin and roxithromycin in recent-onset reactive arthritis. Rheumatol Int. 2013;33:2723\u20139. https:\/\/doi.org\/10.1007\/s00296-013-2794-0.","journal-title":"Rheumatol Int"},{"key":"904_CR24","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/art.27394","volume":"62","author":"JD Carter","year":"2010","unstructured":"Carter JD, Espinoza LR, Inman RD, Sneed KB, Ricca LR, Vasey FB, et al. Combination antibiotics as a treatment for chronic chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum. 2010;62:1298\u2013307. https:\/\/doi.org\/10.1002\/art.27394.","journal-title":"Arthritis Rheum"},{"key":"904_CR25","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/art.1780391211","volume":"39","author":"DO Clegg","year":"1996","unstructured":"Clegg DO, Reda DJ, Weisman MH, Cush JJ, Vasey FB, Schumacher HR Jr, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter\u2019s syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39:2021\u20137. https:\/\/doi.org\/10.1002\/art.1780391211.","journal-title":"Arthritis Rheum"},{"key":"904_CR26","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/rheumatology\/35.12.1330","volume":"35","author":"D Wendling","year":"1996","unstructured":"Wendling D, Racadot E, Toussirot E, Wijdenes J. Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol. 1996;35:1330. https:\/\/doi.org\/10.1093\/rheumatology\/35.12.1330.","journal-title":"Br J Rheumatol"},{"key":"904_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/03009740310000157","volume":"32","author":"O Kaipiainen-Seppanen","year":"2003","unstructured":"Kaipiainen-Seppanen O, Niinisalo H, Korpil\u00e4hde T, Virolainen J. Treatment of reactive arthritis with infliximab. Scand J Rheumatol. 2003;32:122\u20134. https:\/\/doi.org\/10.1080\/03009740310000157.","journal-title":"Scand J Rheumatol"},{"key":"904_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10067-007-0692-0","volume":"30","author":"N Gaylis","year":"2003","unstructured":"Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter\u2019s syndrome. J Rheumatol. 2003;30:407\u201311. https:\/\/doi.org\/10.1007\/s10067-007-0692-0.","journal-title":"J Rheumatol"},{"key":"904_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21323","volume":"53","author":"SD Flagg","year":"2005","unstructured":"Flagg SD, Meador R, Hsia E, Kitumnuaypong T, Schumacher HR Jr. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum. 2005;53:613\u20137. https:\/\/doi.org\/10.1002\/art.21323.","journal-title":"Arthritis Rheum"},{"key":"904_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/RHU.0b013e3180690c1f","volume":"13","author":"D Sanchez-Cano","year":"2007","unstructured":"Sanchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N. Use of adalimumab in poststreptococcal reactive arthritis. J Clin Rheumatol. 2007;13:176. https:\/\/doi.org\/10.1097\/RHU.0b013e3180690c1f.","journal-title":"J Clin Rheumatol"},{"key":"904_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10067-007-0692-0","volume":"27","author":"H Gill","year":"2008","unstructured":"Gill H, Majithia V. Successful use of infliximab in the treatment of Reiter's syndrome: a case report and discussion. Clin Rheumatol. 2008;27:121\u20133. https:\/\/doi.org\/10.1007\/s10067-007-0692-0.","journal-title":"Clin Rheumatol"},{"key":"904_CR32","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/art.24899","volume":"61","author":"T Tanaka","year":"2009","unstructured":"Tanaka T, Kuwahara Y, Shima Y, Hirano T, Kawai M, Ogawa M, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Care Res. 2009;61:1762\u20134. https:\/\/doi.org\/10.1002\/art.24899.","journal-title":"Arthritis Care Res"},{"key":"904_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/RHU.0b013e3181d06f70","volume":"16","author":"MD Wechalekar","year":"2010","unstructured":"Wechalekar MD, Rischmueller M, Whittle S, Burnet S, Hill CL. Prolonged remission of chronic reactive arthritis treated with three infusions of infliximab. J Clin Rheumatol. 2010;16:79\u201380. https:\/\/doi.org\/10.1097\/RHU.0b013e3181d06f70.","journal-title":"J Clin Rheumatol"},{"key":"904_CR34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00296-009-0965-9","volume":"30","author":"MD Schafranski","year":"2010","unstructured":"Schafranski MD. Infliximab for reactive arthritis secondary to chlamydia trachomatis infection. Rheumatol Int. 2010;30:679\u201380. https:\/\/doi.org\/10.1007\/s00296-009-0965-9.","journal-title":"Rheumatol Int"},{"key":"904_CR35","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/art.30272","volume":"63","author":"A Meyer","year":"2011","unstructured":"\u2022 Meyer A, Chatelus E, Wendling D, Berthelot JM, Dernis E, Houvenagel E, et al. Safety and efficacy of anti-tumor necrosis factor \u03b1 therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum. 2011;63:1274\u201380. https:\/\/doi.org\/10.1002\/art.30272The first multicenter series showing efficacy and safety of anti TNF agents in reactive arthritis.","journal-title":"Arthritis Rheum"},{"key":"904_CR36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jbspin.2012.03.001","volume":"79","author":"M Thomas-Pohl","year":"2012","unstructured":"Thomas-Pohl M, Tissot A, Banal F, Lechevalier D. Spectacular evolution of reactive arthritis after early treatment with infliximab. Joint Bone Spine. 2012;79:524. https:\/\/doi.org\/10.1016\/j.jbspin.2012.03.001.","journal-title":"Joint Bone Spine"},{"key":"904_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00296-011-2000-1","volume":"32","author":"A Edrees","year":"2012","unstructured":"Edrees A. Successful use of etanercept for the treatment of Reiter\u2019s syndrome: a case report and review of the literature. Rheumatol Int. 2012;32:1\u20133. https:\/\/doi.org\/10.1007\/s00296-011-2000-1.","journal-title":"Rheumatol Int"},{"key":"904_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jbspin.2016.05.002","volume":"84","author":"A Courcoul","year":"2017","unstructured":"Courcoul A, Muis Pistor O, Tebib JG, Coury F. Early treatment of reactive arthritis with etanercept and 2 years follow-up. Joint Bone Spine. 2017;84:367. https:\/\/doi.org\/10.1016\/j.jbspin.2016.05.002.","journal-title":"Joint Bone Spine"},{"key":"904_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jbspin.2016.02.022","volume":"84","author":"A Brinster","year":"2017","unstructured":"\u2022 Brinster A, Guillot X, Prati C, Wendling D. Anti-TNF treatment of reactive arthritis. A monocentric experience. Joint Bone Spine. 2017;84:237\u20138. https:\/\/doi.org\/10.1016\/j.jbspin.2016.02.022A larger monocentric study upon anti TNF therapy for reactive arthritis.","journal-title":"Joint Bone Spine"},{"key":"904_CR40","doi-asserted-by":"publisher","unstructured":"Gupta V, Mohta P, Sharma VK, Khanna N. A retrospective case series of 12 patients with chronic reactive arthritis with emphasis on treatment outcome with biologics. Indian J Dermatol Venereol Leprol. 2019. https:\/\/doi.org\/10.4103\/ijdvl.IJDVL_519_18 [Epub ahead of print].","DOI":"10.4103\/ijdvl.IJDVL_519_18"},{"key":"904_CR41","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Thorsteinsson B, Geirsson AJ, Krogh NS, Gudbjornsson B. ICEBIO. Outcomes and safety of TNF inhibitors in reactive arthritis: a nationwide experience from Iceland. J Rheumatol. 2020. https:\/\/doi.org\/10.3899\/jrheum.191307The most recent report about anti TNF in reactive arthritis, from a national registry, with long follow-up.","DOI":"10.3899\/jrheum.191307"},{"key":"904_CR42","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/art.40581","volume":"70","author":"LJ Van Mens","year":"2018","unstructured":"Van Mens LJ, van de Sande MG, Menegatti S, Chen S, Blijdorp IC, de Jong HM, et al. Interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses. Arthritis Rheumatol. 2018;70:1994\u20132002. https:\/\/doi.org\/10.1002\/art.40581.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"904_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jbspin.2019.06.012","volume":"87","author":"D Wendling","year":"2020","unstructured":"Wendling D, Prati C, Chouk M, Verhoeven F. Effects of anti-IL-23 and anti-IL-17: the hidden side of spondyloarthritis polymorphism? Joint Bone Spine. 2020;87(1):5\u20137. https:\/\/doi.org\/10.1016\/j.jbspin.2019.06.012.","journal-title":"Joint Bone Spine."},{"key":"904_CR44","doi-asserted-by":"publisher","unstructured":"Zhu L, Zhang Z, Xia N, Zhang W, Wei Y, Huang J, et al. Anti-arthritic activity of ferulic acid in complete Freund\u2019s adjuvant (CFA)-induced arthritis in rats: JAK2 inhibition. Inflammopharmacology. 2019. https:\/\/doi.org\/10.1007\/s10787-019-00642-0 [Epub ahead of print].","DOI":"10.1007\/s10787-019-00642-0"},{"key":"904_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jbspin.2018.01.006","volume":"85","author":"D Wendling","year":"2018","unstructured":"Wendling D, Lukas C, Prati C, Claudepierre P, Gossec L, Goupille P, et al. 2018 update of FrenchSociety for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. Joint Bone Spine. 2018;85:275\u201384. https:\/\/doi.org\/10.1016\/j.jbspin.2018.01.006.","journal-title":"Joint Bone Spine."}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00904-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-020-00904-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00904-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T23:48:05Z","timestamp":1621986485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-020-00904-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1007\/s11926-020-00904-9","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"26 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Daniel Wendling: Occasional interventions (speaking fees, advisory board): AbbVie, BMS, MSD, Pfizer, Roche Chugai, Amgen, Nordic Pharma, UCB, Novartis, Janssen, Celgene, Hospira, Lilly, Sandoz, Grunenthal. Indirect interests: Abbvie, Pfizer, Roche Chugai, MSD, UCB, Mylan, Fresenius Kabi.C Prati: Novartis, Lily and PfizerM Chouk: noneF Verhoeven: Novartis, MSD, Celgene, Amgen and BMS","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"29"}}